A large-scale phase III trial of a KT-110
Latest Information Update: 01 Sep 2021
Price :
$35 *
At a glance
- Drugs Cyproheptadine+prazosin (Primary)
- Indications Alcoholism
- Focus Therapeutic Use
- Sponsors Kinnov Therapeutics
- 01 Sep 2021 New trial record